| abstract |
The present invention relates to immunotherapy by disrupting PD-1/PD-L1 signaling, and specifically provides a method for immunotherapy of cancer patients, comprising administering to the patient an antibody that inhibits the PD-1/PD-L1 signaling pathway, or This antibody is administered in combination with an anti-CTLA-4 antibody. This disclosure also provides a method for immunotherapy of a cancer patient, the method comprising selecting a patient based on the evaluation and administering an anti-PD-1 antibody to the selected subject, the patient being a suitable candidate for immunotherapy, whereby The assessment is that the proportion of cells expressing PD-1 on the cell surface in the test tissue sample from the patient exceeds a predetermined threshold level. The present disclosure additionally provides monoclonal antibodies that specifically bind to cell surface expressed PD-L1 antigens in FFPE tissue samples, and automated IHC for assessing cell surface expression in FFPE tissues with the provided anti-PD-L1 antibodies method. |